Lyell Immunopharma (LYEL)

• Market cap: $522M
• 1 day: 1.03%
• 5 days: -15.32%
• 1 month: -16.13%
• 3 months: 30.1%
• 6 months: 140.45%
• Year to date: -15.29%
• 1 year: 103.23%
• 5 years: -92.73%
• 10 years: -92.73%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Employees: 300